 Do you want to learn how to trade stocks and cryptocurrency? Join our community of traders. Go to richpicksdaily.com and find the next 10-bagger. Hi, how's everybody doing today? I'm your host, Rich, here on behalf of Rich to be live with our very special guest, many-time guest, the chief growth officer of Universal PropTech, Frank Carnaval. How are you doing today, Frank? I'm great, I'm great. How are you? I'm doing fantastic. So big news today. Why don't we talk about it and you can tell us a little bit about what is happening right now with ISBRG and Spotlight 19. Yeah, great day. Long day, we wanted to get all the details right. So I think you recall, I said it on your show a while back that we were really excited about we knew, our partners, we knew what was about to happen and we were waiting for this moment. This is one of many moments. And so finally, we reached a point where Iceberg has announced today that they're in clinical trial. That's important, so they're in clinical trial. Part of the clinical trials are taking place in a Canadian border location or Canadian crossing location. I can't remember there. That's what we're using, Canadian border locations. That's the key. And we have IRAP, so National Research Council of Canada, has granted some money industrial assistance funds for this clinical trial. So we're really excited. We knew this was coming. We had to wait, obviously, that's the challenge of being a publicly traded company and investing a minority stake in a private company. We have to wait till everyone is ready for various announcements. So that's what took a while. There's other things that took a while, but we're excited. We're in clinical trial. I know everyone on the team is excited at Iceberg. We've been quite supportive along the way. So that's what a lot of this was about, was making sure we got that news out. So again, we're pretty excited. Other details, Iceberg also announced two new advisors have joined their advisory board, a great pedigree from Siemens Globally and PepsiCo. So they're bringing in some good expertise to help the business grow post-commercialization. Congratulations. Yeah, thank you. It's a big step for the company and our community has been really excited. They were watching the bids today stack up and it was looking really, really good. And they're like, when's they going to go live? When's they going to go live? And they were watching it all day long and we're just so excited to see this finally go live. So very exciting to see. Yeah, it is. It's challenging having a lot of partners who aren't publicly traded. And so you deal with a whole new layer of complexity that we just don't have, right? We have disclosure, we have certain requirements, but it's interesting to say the least. And we're obviously the small fish in this big pond, but really excited to get this news out today. So let's explain a little bit to the community that's watching. What is the significance of starting clinical trials? So clinical trial is critical. So one of the pieces leading up to this that I don't think originally we expected we had to do was we had to get a Health Canada ITA. It's really, I think, the proper terminology and investigational testing authorization, right? So when you put your hand on the actual device that can scan, again, to remind people, we can scan someone's finger. You put your hand over it. It scans it within several seconds and it's able to read your analytes, assess them. And we teach it through machine learning to identify who is COVID positive and who is COVID negative to make that determination. So all of this is pending the clinical trials and pending Health Canada approval. So we had to get through that ITA process. Got through that, took a little bit longer than we had liked, but we got through that and was just setting up this clinical trial start. So there's two phases to it. Iceberg will put up more information when they're able to, but we're in that first stage of it where again, we're teaching, we said this in the past, it is learning from scans that are done on people scans are taking place as being compared against PCR scans and PCR tests to teach it what is positive, what is negative. And it will build up from there. And in a short term, we will figure out how, you know, what Duncan's working on, the CEO of Iceberg is to that refine that specificity, right? To really calibrate it so that it knows, yep, we're pretty confident, just going to say yes or no properly and accordingly. So we're kind of excited, we're in that first stage and that is a very critical stage. Oh yeah, absolutely. That's really exciting to see you guys evolve. I remember when we first started talking and you know, we've been doing this quite a bit and our investors and our community got really excited. Stock went up like crazy. We've started when it was around 20 cents, went to like around 70 and the stock came back down and gave a lot of investors an opportunity to get in again to be quite frank. So a lot of our investors have kind of come back in at these lower levels and to see this news now, I think they're going to be very excited. Now, what does this mean for investors? Yeah, so I think for investors we're certainly one step closer to having a, again, we can't say one way or another what Health Canada will do with it in the end, but we're one step closer to having a commercialized product. So from that perspective, it's significant. Huge. I would just say, it's one of those things where we understood when we did our due diligence that sort of expected timeframe, which again, there's certain expectations and some things were longer and other things we think are going to be quicker. So it just sort of works out in the wash. We're still excited that we will have a solution that pending approval will still be quite relevant. If you're paying attention to what's happening from a COVID perspective will still be quite relevant. And look in the last few days alone, you really pay attention to where the governments are going even in this country in Canada and the United States for that matter. It's rapid testing. Rapid testing is that next layer of if we're not achieving herd immunity, then what are you going to have in place to make sure that people are still safe going into facilities, buildings, schools, campuses, it will be rapid testing. So we're still on a good timeframe to be relevant for that. What is, you mentioned the Canadian border location. What is that all about? Well, you know, so I guess there'd be a few without giving away exactly where you can imagine to leave this country, there's only a few places you can leave this country from. So from that context, it's important to know just as we don't want people coming into this country without doing tests and being processed accordingly for COVID perspective, we're also doing the same thing for people leaving. So I think the relevance is we're not in a mall, we're not in a sort of a rather small location, we're in a significant location that's obviously processing people. And it's the issue of the day, every day, people wondering, how are people getting in? We know too many people can't get out of this country, but clearly people can get into it. So the relevance is making sure we found locations that you get a significant diversity of testing subjects and that's gonna be obviously critical to having the right solution in the end. So that's definitely the relevance. It's not a very homogeneous group, you're gonna get all kinds of people being tested and we're quite excited about that. Why did it take so long to announce these updates? So, great question. I think with a lot of our investors, some are more active than others and texting and reaching out and making comments and statements, we do our best to try to respond and reach out to as many of them as possible when they ask these questions. We're a bit of a victim of our own success, right? So we have a company that since the last time we talked, we are debt-free, have a solid, we're certainly more profitable than we were the previous year, have a solid foundation, spending more money, resources and growing our business and really bringing in more products, more solutions. So exciting that part of the story is quite exciting. And then we did this with iceberg and this is a very exciting story. And I think a combination of since the last time we've come out, people really just wanna hear about iceberg. And I get it, that's very sexy and exciting. And so there's other things that we're doing, obviously. So I think it's a combination of, again, it's trying to get messaging, trying to get information out. And so it's difficult when we're not in complete control of that. And that's fine. That's just how it works when you make minority investments. So there's a lot of coordination with a lot of organizations and much larger organizations. So that's a bit of that delay. And I think the second part of that is really, as I said earlier, the Health Canada ITA and don't wanna get into too much of that. It was just something that I think we didn't assume early on that that was something we had to do and that's something we did have to do. And it was something that got extended a little bit longer than we expected. So that combination really added to the length of time. Certainly the last time I spoke to you didn't expect to have to do these things. And that's really the extent of that. I think going forward, certainly from a company perspective, we have so many exciting things we're doing within our day-to-day business that I think we've learned we'd really have to really demonstrate to people, here's what we're doing. Here's the singles and doubles we do all day long. And we have some other news we'll come out on that in the near future. But it is exciting what we do day-to-day. And I think we have to match that in general and make sure people hear all the stories and all the narratives of what we're up to as opposed to just the iceberg one. But I do get why iceberg is exciting. It is pretty relevant today. We have a lot of long-term investors that are just buying whole type guys. To be quite honest with you, I feel like you guys have moved very quickly. I think investors are impatient. They want results. Really, really rich. I will say this, Rich. I will say this for a lot of those people as well is that I've been in business for over 20 years developing different projects and things. And so from the investor community, they might not know me from Adam. And so I do understand that. And so we have to earn that type of respect and earn that appreciation that if I say we're working on something and things are going to happen, I'm not lying about it. It's just there's things that the ingredients are going to having a successful project, a successful investment. So I think there's just a whole, as you pointed out, I think long-term investors understand, okay, things don't happen that fast, but yet things are happening fast. And so it's just really trying to satisfy the appetite of many investors. But again, I think we're doing it. We'll probably share much more of our singles and doubles than just the home runs. So we'll look for that, I think going forward. But next week I'm speaking at a Q2 investor summit and we'll have obviously information like this to share and bring people up to date and really answer all the investor questions as much as I can. I think I'm booked for two days worth of questions. So pretty excited. Yeah, and I wanted to thank you for that because we do have members that reach out to you and they always love the fact that you respond to that, whether it's on Twitter, email, Instagram. Yeah, I think, hey, there are backbone. I mean, I worry about and tell them all the time and my response is we worry about customers or we worry about our staff and we worry about investors. You need to worry about all three of them fairly evenly because kind of just do one, you're in trouble with the others. So absolutely, I appreciate when people reach out, I do my best to respond when I can. And obviously sometimes are trickier than other times. Now, you mentioned it a little bit, the singles and doubles. So do you guys have any irons in the fire that are not iceberg related? Yes. Perfect, that can catapult revenue and future growth. I know that's a question that I want to address. You know, there is, I think, it's a really great question because we spent that sort of first quarter, I mean, at least when I came in, it's been just under a quarter of bringing in new products, bringing in new solutions and trying to embed them within our operations and go out and sell and sell it and market it and generate that. So there's a bit of, we loaded up the deck with some great air purification technologies and all those are underway. There's communications with them, there's proposals you've been making, so they're all part of what we're trying to do going forward, right? So it's, you know, we make investments, we integrate, we scale and repeat. That's literally what we have on our investor deck. And so we bring in some batch of solutions, we look at how best to make them part of our solutions that going forward, you know, and we get some success, we do it again. So I think that first stage of indoor air quality is pretty much through. There's a lot in there that we've played with. There could be some more stuff. There's a whole slew of building performance, you know, more artificial intelligence technologies. Absolutely, we've talked about in the past, way more to happen and way more on the energy resources group where, you know, from investment, it could be anywhere from investments to acquisitions to strategic partnerships. Absolutely, there's a whole slew of them. And it's just a sequence and a method to our madness. And I don't, we're definitely not stopping on iceberg. So many more things to come. Now, speaking on that, let's just say spotlight 19 doesn't pass clinical trials. Can spotlight 19 still be used by private companies? You know, it's a good question. So I don't know all the details, but so when you're done and you brought your, you're testing your clinical trials and you've done your two stages and you bring them for final approval, think of it as there's an efficacy level of what you can achieve, right? So again, at the end of the first stage, if you didn't have a solution that had a very good specificity that you were very comfortable with to then say, let's lock it up and now run it through our second phase trial. Why would you lock it up and put it through your second phase trial, right? So there's a certain confidence of it's doing what we think it's, you know, it's supposed to do and we lock it up and we submit it for that second phase. The second phase in the end is really more about in the end determining are you, I think it's a level one product or are you level two? Level one would be say it's more for, you know, true diagnostics, true, you know, I can determine in a hospital and somewhere that this can detect COVID and this is that final line or is it a sort of level two where it can be used in private businesses, in places where like arenas and other places where it's used to prevent access and it's sort of a triage effect where, yeah, you can't get access and depending on what level it's approved at, okay, you don't get access, now go do that PCR test if you wanted really to get access because we see you're positive. So there are different stages of it. You know, I think from my perspective in the way that we looked at this remade investment, it's not, is it going to work or not? It's how well will it work and then let the market play out based on what those approvals are, right? So you're absolutely right. Can it be used in different fashions or different, can it be sold and licensed people probably could. And I think once approvals are achieved, you can then determine how best to take advantage of whatever level that it has secured. So we'll let Duncan, the CEO of Iceberg, continue to manage that. He's doing a great job. He's got a great team in there too to ensure that this is a great technology, that there's no shortcuts taken. I guarantee that. He's very, you know, he just takes his time and he does it right and there's no cutting corners here. So we're very excited about that. If there's one thing that you want investors to know about today before we say goodbye, what would it be? You know, I think everything I said it was, it is. And as additional information can come out, they can understand we were extremely positive from day one because we understood and still understand who all the partners are and who's involved in this and the credibility they all bring that hasn't gone away. That's still there. Today is the snapshot of some of that credibility. And, you know, there's no one can say to me that, well, is this product really gonna work when you can secure a Canadian border location? That just doesn't happen if you're a fly by night. So we're very excited, you know, it's very credible. And honestly, Chris and I, our CEO, we just, we can't wait for all the information to come out in due course. But we just want investors to know we were very serious about this. We continue to be serious and excited and very bullish on the technology and, you know, continue to look for our notes, our updates and follow along. Well, super excited to see it unfold. Thank you for joining us today again, Frank. Oh, my pleasure, Rich, thank you. And guys, remember before you invest in anything, please do your due diligence, do your research. Rich TV Live is strictly for information and education purposes. If you liked the video, smash the like button, comment down below, share the video everywhere and subscribe. I'm gonna be honest with you, Frank, UPI has become one of my favorite companies. You guys, you mentioned it, no debt. And that is huge for our community and our investors. Baby market cap, tight share structure, growing revenue, strong management team. I'm really impressed with what you guys are doing, Frank. Thank you for being a part of a great company and bringing this to our community. Love to invite you back on our show anytime you have any big, breaking news like this today. Thank you for bringing the news here to Rich TV Live. The chief growth officer of Universal PropTech, Frank Carnabelle, have a great day, everybody. If you're not winning, you're not watching. We bring you the winners and we bring them to you first. Have a nice day, everyone.